In the same context, a previously mentioned study by Nicolazzo et al. included 24 patients with advanced NSCLC treated with nivolumab and assessed CTCs and CTC PD-L1 expression on blood samples obtained at baseline, 3 months, and 6 months post-treatment [37]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.